Beyond COVID: The Pipeline of mRNA Vaccines and Therapeutics
The COVID vaccines proved the concept at massive scale, but the mRNA pipeline extends far beyond respiratory viruses. RSV vaccines using the mRNA platform have now been approved, offering better protection than protein-subunit alternatives. Influenza mRNA vaccines in Phase 3 trials have shown improved efficacy over traditional flu shots, potentially solving the annual formulation problem by enabling faster updates to match circulating strains.
Personalized cancer vaccines represent the most ambitious application. By sequencing a patient’s tumor and identifying mutations unique to their cancer (neoantigens), researchers can design a customized mRNA vaccine within weeks. A landmark 2023 New England Journal of Medicine study showed that a personalized mRNA vaccine combined with immunotherapy reduced melanoma recurrence by 44% compared to immunotherapy alone in a Phase 2b trial.
HIV has resisted vaccine development for 40 years due to its extreme mutation rate and ability to hide in immune cells. The mRNA platform offers new strategies: by targeting conserved viral regions or training multiple arms of the immune system simultaneously, researchers hope to overcome barriers that defeated previous approaches. Phase 1 trials of mRNA-based HIV vaccines are now in progress.
